Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 2, 2008, Pages 558-567

  Minuesa, Gerard ^a   Purcet, Sergi ^b   Erkizia, Itziar ^a   Molina Arcas, Míriam ^b   Bofill, Margarita ^a,c   Izquierdo Useros, Nuria ^a   Casado, F Javier ^b   Clotet, Bonaventura ^a   Pastor Anglada, Marçal ^b   Martinez Picado, Javier ^a,c,d  

^a IrsiCaixa Foundation   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MEMBRANE PROTEIN; ORGANIC CATION TRANSPORTER; PROTEIN SLC22; PROTEIN SLC28; PROTEIN SLC29; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; UPREGULATION;

ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HIV; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE TRANSPORT PROTEINS; RNA, MESSENGER;

EID: 38749131935     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.131482     Document Type: Article

References (40)

1. Aiba T, Sakurai Y, Tsukada S, and Koizumi T (1995) Effects of probenecid and cimetidine on the renal excretion of 3′-azido-3′-deoxythymidine in rats. J Pharmacol Exp Ther 272:94-99.
2. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, Balestra E, Calio R, and Perno CF (2002) Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 68:479-488.
3. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, and Young JD (2004) The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447:735-743.
4. Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP, and Pastor-Anglada M (2004) Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther 9:993-1002.
5. Chang C, Swaan PW, Ngo LY, Lum PY, Patil SD, and Unadkat JD (2004) Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol 65:558-570.
6. +-independent L-carnitine transporter in enterocytes basolateral membrane. J Cell Physiol 202:929-935.
7. Errasti-Murugarren E, Pastor-Anglada M, and Casado FJ (2007) Role of Cnt3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. J Physiol 582:1249-1260.
8. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
9. Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, and Pastor-Anglada M (2004) Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 112:959-966.
10. Fridland A, Connelly MC, and Robbins BL (2000) Cellular factors for resistance against antiretroviral agents. Antivir Ther 5:181-185.
11. Gray JH, Owen RP, and Giacomini KM (2004) The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447:728-734.
12. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, and Schomig E (2005) Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A 102:5256-5261.
13. Hong M, Schlichter L, and Bendayan R (2001) A novel zidovudine uptake system in microglia. J Pharmacol Exp Ther 296:141-149.
14. Hu H, Endres CJ, Chang C, Umapathy NS, Lee EW, Fei YJ, Itagaki S, Swaan PW, Ganapathy V, and Unadkat JD (2006) Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol Pharmacol 69:1542-1553.
15. Jutel M, Watanabe T, Akdis M, Blaser K, and Akdis CA (2002) Immune regulation by histamine. Curr Opin Immunol 14:735-740.
16. Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, and Kroemer HK (2007) Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet 46:449-470.
17. Koepsell H and Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666-676.
18. Koepsell H, Lips K, and Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmacol Res 24:1227-1251.
19. Lee W and Kim RB (2004) Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44:137-166.
20. Leung S and Bendayan R (2001) Uptake properties of lamivudine (3TC) by a continuous renal epithelial cell line. Can J Physiol Pharmacol 79:59-66.
21. Mahony WB, Domin BA, Daluge SM, and Zimmerman TP (2004) Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir. Biochem Pharmacol 68:1797-1805.
22. Mangravite LM, Xiao G, and Giacomini KM (2003) Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. Am J Physiol Renal Physiol 284:F902-F910.
23. Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, Lloberas J, Casado FJ, and Pastor-Anglada M (2001) Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5′-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59:1542-1548.
24. McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, and Kashuba AD (2006) Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 318:1068-1075.
25. Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D, and Pastor-Anglada M (2003) Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 101:2328-2334.
26. Molina-Arcas M, Marce S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B, Montserrat E, Gil J, Colomer D, and Pastor-Anglada M (2005) Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19:64-68.
27. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J, and Casado FJ (2005) Cell entry and export of nucleoside analogues. Virus Res 107:151-164.
28. Purcet S, Minuesa G, Molina-Arcas M, Erkizia I, Casado FJ, Clotet B, Martinez-Picado J, and Pastor-Anglada M (2006) 3′-Azido-2′,3′- dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. Antivir Ther 11:803-811.
29. Schneider E, Machavoine F, Pleau JM, Bertron AF, Thurmond RL, Ohtsu H, Watanabe T, Schinkel AH, and Dy M (2005) Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J Exp Med 202:387-393.
30. Smith CL, Pilarski LM, Egerton ML, and Wiley JS (1989) Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood 74:2038-2042.
31. Soler C, Felipe A, Garcia-Manteiga J, Serra M, Guillen-Gomez E, Casado FJ, MacLeod C, Modolell M, Pastor-Anglada M, and Celada A (2003) Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways. Biochem J 375:777-783.
32. Soler C, Valdes R, Garcia-Manteiga J, Xaus J, Comalada M, Casado FJ, Modolell M, Nicholson B, MacLeod C, Felipe A, et al. (2001) Lipopolysaccharide- induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms. J Biol Chem 276:30043-30049.
33. Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, Oku A, Shimane M, and Tsuji A (2000) Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem 275:40064-40072.
34. Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, et al. (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 35:341-348.
35. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, and Clark RE (2007) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther, in press.
36. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, and Hughes TP (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697-704.
37. Wiley JS, Snook MB, and Jamieson GP (1989) Nucleoside transport in acute leukaemia and lymphoma: close relation to proliferative rate. Br J Haematol 71:203-207.
38. Zhang J, Visser F, King KM, Baldwin SA, Young JD, and Cass CE (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26:85-110.
39. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, and Giacomini KM (2000) Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 28:329-334.
40. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847-8857.